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ABSTRACT
This review addresses the immune consequences ofChlamydial infections in pregnancy and in vitro
fertilization (IVF) outcome. In pregnancy, many works have shown the risk for perterm labor,
preterm birth, or miscarriage with current infection, and stress the need for screening and treatment
early in pregnancy. IVF outcome needs to be studied in relation to specific markers like inflammatory
cytokines and secretory antibodies to the 60 kD heat shock protein (hsp60) and to Chlamydia, to
determine their ability to predict and influence pregnancy outcome. (C) 1996 Wiley-Liss, Inc.
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hlamydial infection elicits an immune re-
sponse involving humoral and cellular immu-
nity. Mild or recent infection can be controlled by
neutralizing antibodies like IgG and IgA including
secretory IgA.
Untreated or unsuspected infections can become
chronic, and cause damage related to inflammation
through cellular immune activation. Inflammatory
cytokines are released as a consequence of pro-
longed antigen presentation and may not be suffi-
cient to resolve long ongoing infections but are suf-
ficient enough to maintain an inflammatory state.
In pregnancy and IVF outcome, sequelae differ ac-
cording to the specific immune responses that are
induced.
PREGNANCY
Chlamydial cervicitis of recent origin, in the ab-
sence of tubal damage, does not impair fertilization
or egg implantation. Detection prevalence in preg-
nancy varies from 6%-40% according to the studies,
settings and populations. Seroprevalence varies
from 15%-35% according to the populations. The
risk for preterm labor and preterm birth 1,2,3 but not
premature rupture of membranes 1’4 is significantly
higher in pregnant women with a positive chlamyd-
Article
ial detection and increases further when bacterial
vaginosis is also present. Intra-amniotic chlamydial
infection can persist with intact membranes and
without clinical symptoms. Antichlamydial antibod-
ies have also been associated with perinatal compli-
cations,s-7 If exposure occurs during pregnancy, it
may be permitted by immunosuppression and/or
cervical ectopy. Chorioamnionitis can occur with
cytokine emission in the amniotic fluid, promoting
prostaglandin PGE2 secretion and ocytocic se-
quelae. Hsp60 expression have been found identi-
cal in normal pregnancies and preterm birth by
immunocytochemistry, showing that hsp60 is
abundantly expressed in placenta; however, anti-
bodies to hsp60 have not been studied in that work.
In untreated mothers completing their preg-
nancy, the contamination risk factor for the foetus,
which is mildly protected by the maternal antibod-
ies, is 20%-50% for conjunctivitis and 10%-20% for
pneumoniae and respiratory disease syndrome with
the likely sensitization of the the infants to further
chlamydial infections. These findings stress the
need for chlamydia detection at 24-26 weeks ofges-
tation. 10
Pregnancy can be interrupted by chlamydial in-
fection. Most of the studies on current infection
Received September 15, 1996
Accepted October I, 1996CHLAMYDIA, PREGNANCYAND IVF ASKIENAZY-ELBHAR
correlate a late miscarriage with a positive detection.
Early spontaneous abortions have been associated
with chlamydial antibodies but some authors 11 do
not find significant differences with control popula-
tions. A recent screeninglz found that chlamydial
infection was the second most frequent cause for
recurrent foetal losses. Another recent work finds
a positive correlation between hsp60 antibodies to
the chlamydial 60kD heat shock protein (chsp 60)
and spontaneous abortions 14. More studies are
needed to implicate precisely the immunopatho-
genesis of past or current chlamydial infection in
spontaneous abortion.
ECTOPIC PREGNANCY (EP)
In contrast to infection during pregnancy, numerous
authors have associated the risk for ectopic preg-
nancy with a past chlamydial infection. The mecha-
nism is tubal function impairment or tubal alter-
ation. In fact chlamydial antibody prevalence
3 and
chlamydial tubal impairment are the most frequent
causes of EP, often revealing an inapparent past
infection. Recent studies5 have demonstrated via-
ble chlamydiae in the tubes by mRNA transcripts.
Hsp60 antibodies have been associated with tubal
scarring in the pathogenesis of EP6 through re-
peated exposures or sensitization to Chlamydia.
After ectopic pregnancy many women undergo
IVF because of tubal removal or plasty. But it ap-
pears now that chlamydial antigens remain inside
the tissues and endometrium possibly affecting
IVF outcome.
IVF
Most of the studies report an unchanged fertiliza-
tion rate after IVF in chlamydial infected vs. non-
infected patients. This can suggest that the oocyte
capacity to be fertilized is not impaired by the infec-
tion, recent or past even with high antibodies titers.
In contrast, after embryo transfer a number of pa-
tients either do not reach pregnancy, or suffer early
spontaneous abortions. The results are controversial
because of the great variability of anti-chlamydia
antibody detection methods. Some works have used
detection (culture, antigen detection DNA or
mRNA detection with or without amplification),
others have used chlamydial structural antibodies,
or anti hsp60 antibodies, in serum or genital fluids,
with various degrees of specificity (genus specific
antibodies, genus or bacterial specific hsp). In some
studies 7,18,19,2,21,22, there was no correlation between
pregnancy rate and the presence of antichlamydia
antibodies. In contrast, other authors found a nega-
tive correlation between anti chlamydia antibodies
and a successful IVF OUtcome23’24’25’26’27’28’29. Because
of the established relation between tubal infertility
and hsp60 antibodies3,3,32’33 it seemed possible to
hypothesize a link between hsp60 antibodies and
a reduced pregnancy rate.
Hsp60, stress response protein for both chla-
mydia and host34’35, is a potent immunogenic agent
leading to antibody secretion, and inflammation in-
duction36’37 leading to cytokine secretion through
antigen presenting cells.38 Being homologous to the
human hsp60, bacterial hsp60 can trigger autoanti-
body formation in the host, and development of
delayed hypersensitivity reactions building tissue
damage in the upper genital tract and also in remote
areas like joints and liver. Maternal or embryo hsp
expression is not normaly harmful to the mainte-
nance of pregnancy, unless the mother has been
sensitized previously to a bacterial hsp. In that case,
expression of maternal or embryo hsp60 will reacti-
vate the lymphocytes previously sensitized to
hsp60, and this will induce a proinflammatory im-
mune response which might lead to immune rejec-
tion. After IVF, embryo implantation in a previously
infected endometrium, possibly still hiding altered
or impotent elementary bodies, is a challenge.
Embryo and decidua secrete proinflammatory
and anti inflammatory cytokines like TNFx, IL,
growth factors, and different kinds of hsp among
which is hsp60. Recent studies on animal models
demonstrate that implantation and embryo devel-
opment are linked to endogenous and exogenous
growth factors; uterine modifications triggered by
steroid hormones are settled through local growth
factors.39-41 To date four cytokines are known as
regulators of uterine proliferation and differentia-
tion, and embryo implantation: EGF, CSF1, LIF,
and ILl. The latter is a proinflammatory, metabolic
and immunologic cytokine mediating inflamma-
tion42 and is necessary for endometrium-embryo di-
alogue. Decidua and endothelial cells produce
TNFot, another proinflammatory cytokine. The
embryo itself produces antigens, cytokines like
IFNy and tau.43 TNFot, IL 10. IFNy and TNFot are
predominant in placentas of aborting foetuses (Th
immune response). IFNy activates NK T-cells,
IL10 and IFN tau are immunosuppressive and anti-
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abortive (Th2 immune response). Early inflamma-
tory reaction is necessary for implantation (ILl,
LIF) but its deregulation can totally damage im-
plantation39.
Hypersecretion of TNFa, produced by a latent
infection in the endometrium, as in chronic chla-
mydiosis, induces other such cytokine production
as ILl, IL8, IL6 and CSF. CSF inhibits LIF in
infertile women and could cause embryo rejection
by PGE2 production, or at high concentrations, in-
hibit implantation. ILl has been demonstrated in
Chlamydia infected fallopian tube tissue and could
act by anti angiogenic properties, opposite it’s
physiologic proimplantation (pseudo-inflammatory
action).
Embryos secrete hsp in response to stress, or
physiologically as protein shedding. Hsp60 and
70 have been demonstrated during the pre-and
peri-implantatory phase in the embryo.
44 It is thus
evident that in the implantation phase immune
modulators are already normally present. Even
without inflammation, the role of immune media-
tors in embryo implantation is not precisely known.
Following T-cell activation or suppression, an in-
flammatory reaction can switch from Thl to Th2.
It has been demonstrated that chlamydial antibod-
ies and chlamydial hsp are related to induction
of inflammatory cytokines,37’45 hsp strongly induces
T-cell and macrophage activation and cytokine
production, and that the immune response is
restricted by certain regions of the MHC.46 There-
fore, we may assume that cytokines secreted by
infection-activated T-cells and macrophages send
a wrong message to the developing embryo and
disrupt the balance between pro and anti-inflam-
matory cytokines, not only impairing embryo
growth, but also suppressingembryo rejection by the
maternal tissue. Furthermore, as in other immuno-
inflammatory processes, subsequent chronic inflam-
mation, and autoimmune reaction may be due to a
non-specific stimulus, of chlamydial, microbial, or
other hsp origin
47 cross reacting with not only mater-
nal but also embryo’s hsps.
A partner’s chlamydial infection can also play a
role in the female’s rejection of the embryo: chla-
mydial auto antibody-coated sperm activate, after
intercourse, women’s T-cells which in turn produce
inflammatory cytokines.
48 High levels of inflamma-
tory cytokines like IL6 have been found in men
affected with chlamydia-associated prostatitis49,
which also activate the woman’s genital tract T-
cells during and after intercourse.
According to this hypothesis, to link embryo re-
jection to chlamydial infection, we had to demon-
strate that an inapparent or subclinical inflammation
could permanently activate T cells, macrophages
and B-cells by presenting altered antigens and heat
shock proteins to secrete IFN/and TNFo through
interleukin activation. In a recent prospective study,
we have attempted to look for evidence ofinflamma-
tion in the cervical mucus related to local chlamydial
IgA, and we found significant correlation. Chlamyd-
ial antigenicity has been proven by local specific se-
cretory antibodies, although circulating antibodies
were not found. Those patients with a past chlamyd-
ial infection had significant titers of inflammatory
cytokines. The correlation between inflammatory
cytokines, chlamydial hsp, IgA, and a poorpregnancy
outcome has been recently demonstrated5. The pos-
siblity that a past chlamydial infection enhancesTh2
inflammatory processes during earlyembryo implan-
tation and thus impairs it is then assessed. But this
antigen presentation is MHC restricted. Recently
sl
it has been shown that genetic susceptibility or resis-
tance to tubal damage inCT infected macaques was
correlated toMHC class I antigens. Similarly suscep-
tibility to endometriosis has been associated with ex-
pression ofMHC class antigens, which regulate the
resistance to lysis by NK T cells. Class II MHC,
TNFot and HSP70 genes are very closely located on
the same chromosome and play a role in up- and
down-regulation of antigenicity, inflammation, and
autoimmune-delayed hypersensitivity.
36MHC class
I antigens as well as polymorphism in the gene en-
coding TNFo has been associated with severe scar-
ring in trachoma, confirming the genotypic sus-
ceptibility to severe infection. 5z MHC1 antigen
expression also modulates the embryo’s susceptibil-
ity or resistance to lysis byNK T-cells. If it certainly
is necessary to develop research on MHC-related im-
mune reactions towards chronic Chlamydial infec-
tion to predict IVF outcome, it seems mandatory to
look for inflammation by screening for local chla-
mydial antibodies, and not only in Chlamydia tracho-
matis seropositive patients. A recent work confirmed
the correlation between MHC antigens, antibodies
to hsp60 and significant adverse sequelae3. Al-
though controversial results on the relation between
hsp60 antibodies and pregnancy rates have been re-
ported54’z5 with significant methodological differ-
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ences between studies, it seems more likely, that
hsp60 antibodies are associated with adverse IVF
outcome or early spontaneous abortionszS. In this
study, the lack ofcorrelation between pregnancy rate
and serologic evidence ofpast chlamydial infection is
consistent with the findings ofClaman54. Our results,
like otherworks (50), correlate the secretory IgACT-
positivity to inflammation.
To see if chronic chlamydial infection could pre-
dict IVF outcome, we studied a series of infertile
couples. In an ongoing retrospective study, we
looked for antibodies to hsp60 and 70 from chla-
mydial, E. coli, and human origin in those patients.
So far, the results are surprising in terms of the
relation between past chlamydial infection, infertil-
ity, and IVF outcome. We tried to see in what way
a past chlamydial infection could impair assisted
reproduction attempts in infertile patients undergo-
ing IVF. Some CT seropositive women did not
have anti-chsp60 antibodies, some had anti-chsp
antibodies and/or anti E. coli hsp60 antibodies, and
some of them had only anti-human hsp60 antibod-
ies. Those first results already suggest that all past
chlamydial infections do not lead to chsp60 antibod-
ies, and that chsp antibodies are associated with
chronicity and unsuccessful treatment. Secondly,
some infected patients may have only E. coli hsp60,
but still have human hsp antibodies. A recent study
(in press) found that women having human hsp60
antibodies were also reactive with a conserved epi-
tope ofchlamydial hsp60, showing that presensitiza-
tion is sufficient for one or the other hsp60 to launch
the antibody reaction, and infected women respond
differently according to their genetic susceptibility.
This supports the facts already reported that hsp60
antibodies are associated with severe sequelae of
chronic upper genital tract chlamydial infections55,56.
I can conclude that neither anti-structural chla-
mydia antibodies or anti-chsp60 antibodies are the
golden marker to predict IVF outcome in Chla-
mydia infected couples. We need more prospective
studies to define the marker, or the association of
markers. After that, other studies will also be neces-
sary to know how to improve the prognosis of IVF
outcome by antibiotic, anti-inflammatory or immu-
nomodulating treatments.
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